Pinpointing How Rituximab Stops Leaky Kidneys (1 of 2) (IMAGE)

American Association for the Advancement of Science (AAAS)

Pinpointing How Rituximab Stops Leaky Kidneys (1 of 2)

Caption

The authors made the rituximab fluorescent (FITC) and demonstrated that it binds to kidney sections (above) and to podocytes in culture (below). This is a major paradigm shift, as rituximab was thought to bind only to B-lymphocytes, the cells making immunoglobulins. This image relates to a paper that appeared in the June 1, 2011, issue of Science Translational Medicine, published by AAAS. The paper, by Dr. Alessia Fornoni of the University of Miami Miller School of Medicine in Miami and colleagues, was titled, "Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis."

Credit

Image © Science/AAAS

Usage Restrictions

Please cite the owner of the image when publishing. This image may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.